Pharmacological studies have indicated that miR-122, delivered by AMSC-EVs, modulates the expression of targeted genes in HCC, including CCNG1, ADAM10, and IGF1R, subsequently enhances sorafenib sensitivity and the anti-tumor effectiveness of HCC, both in vitro and in vivo. Here, CCNG1 is linked to hepatocellular carcinoma.